Experimental cancer drug GEN1078 tested in just 3 people – trial halted early
NCT ID NCT06771921
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tested an experimental drug called GEN1078 in 3 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check for side effects and see how the body processes the drug. The trial was terminated early, so results are very limited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
GEN1078 (an experimental drug)
What this could lead to
If it works, this could point toward a new treatment option for advanced solid tumors that have not responded to other therapies.
What could go wrong
This trial was terminated early with only 3 participants, so we have very little data. It is too early to know if GEN1078 is safe or effective, and many early cancer drugs fail to show benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centro Integral Oncologico Clara Campal
Madrid, Spain
-
Clinica Universidad de Navarra
Pamplona, Spain
-
Hospital Universitari Vall d'Hebron
Barcelona, Spain
-
Hospital Universitary Fundacion Jimenez Diaz
Madrid, Spain
-
NEXT Oncology Madrid
Madrid, Spain
-
Righshospitalet (Copenhagen University Hospital)
Copenhagen, Denmark